Spotlight On... Inovio pays $5.5M for jet delivery tech

Inovio Pharmaceuticals ($INO) shelled out $5.5 million for Bioject Medical Technologies' assets, getting its hands on needle-free jet injection technology with plans to incorporate the tech with its own. Inovio hopes to use Bioject's devices, which use high pressure gas or springs to propel liquid medicine into skin for immunization, with its DNA vaccines. Though it doesn't market any vaccines, Inovio's clinical pipeline includes vaccines for flu, HIV, Ebola, and MERS and preclinical programs in Zika, dengue, Chikungunya and RSV. It also has proof-of-principle human data showing a "significant" immune response for its universal flu vaccine and HIV DNA vaccine. Release

> A late flu outbreak is active in 37 U.S. states, according to a recent CDC report. Report

> New research shows that vaccine refusal is contributing to outbreaks of measles and pertussis in the U.S. More

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> German biotech Medigene said a data and safety monitoring board recommended advancing the company's dendritic cell vaccine to Phase II in acute myeloid leukemia. Release

> Brazil's Butantan Institute signed on with stabilization technology specialist ViveBio for work on a Phase III dengue vaccine trial. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.